| Bioactivity | Basiliximab (CHI 621) is a recombinant chimeric murine/human IgG1 monoclonal anti-interleukin-2 receptor antibody. Basiliximab can be used for the research of renal transplantation[1]. |
| Target | Interleukin-2 receptor |
| Invitro | Basiliximab specifically inhibits T lymphocyte proliferation by binding to the IL-2Rα[1].Basiliximab binds only to activated lymphocytes and macrophages/monocytes[3]. Basiliximab does not affect resting T lymphocytes that do not express IL-2Rα[3]. |
| In Vivo | Basiliximab (CHI 621) (0.07 mg/rat; i.v.; once) decreases total placental natural killer cells in reduced uterine perfusion pressure (RUPP) rats[2]. Animal Model: |
| Name | Basiliximab |
| CAS | 179045-86-4 |
| Appearance | Liquid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. McKeage K, et al. Basiliximab: a review of its use as induction therapy in renal transplantation. BioDrugs. 2010 Feb 1;24(1):55-76. [2]. Cunningham M W, et al. The Role of Interleukin‐2 (IL‐2) in Natural Killer Cell (NK) Activation and Hypertension in a Preclinical Rat Model of Preeclampsia. The FASEB Journal, 2018, 32: 911.1-911.1. [3]. Chapman TM, et al. Basiliximab: a review of its use as induction therapy in renal transplantation. Drugs. 2003;63(24):2803-35. |